Skip to page content

StoriesMore

graphen tattoo
News
BSU101 Blog KW
News
Vertex
News
Harvard innovation labs 2024
News
Zaid Ashai - Nexamp 2
News
Dylan Zajac - Computers 4 People - MA Office 2
News
RouxKickoff 05
News
Inno Fire Awards
News
Eoin Hinchy
News
Boston Speaks Up Cam Brown
Profiles
14 Motif FoodWorks Phyical Lab Credit Webb Chappell
Profiles
Aleia Bucci, Jeremiah Pate
Profiles
Guy Hudson
Profiles
Boston Speaks Up Aisha Chottani
Profiles
Waeve Founders
Profiles
Boston Speaks Up Mike Salguero
Profiles
Pamela Shaddock, co-founder and Dianne Austin, CEO
Profiles
Jake Tamarkin, CEO of Everyday Life Insurance
Profiles
Crumpled one dollar bills on blue background
Inno Insights
Sports gambling
Inno Insights
Venture capital
Inno Insights
Compensation
Inno Insights
Financial growth
Inno Insights
Proptech startups
Inno Insights
Corporate investments
Inno Insights
Sam Bankman-Fried, FTX
Inno Insights
Hand grasping at fluttering money
Inno Insights

More

May
16
TBJ

See All Events

Want to stay ahead of who & what is next? Sent daily, the Beat is your definitive look at Boston’s innovation economy, offering news, analysis & more on the people, companies & ideas driving your city forward. Follow the Beat.

Sign Up
May
16
TBJ

See All Events

SpotlightMore

See More
See More
See More
See More
See More
See More

Thought Leadership from our Partners

May 10, 2024

The Cambridge mall’s former food court will become a new concept slated to open this fall. Here are some of the future tenants.

May 10, 2024

John Hancock saw an 18% increase in core earnings, reporting $335 million in earnings for Q1. But it also reported an $80 million loss in net income.

May 10, 2024

The cancer hospital says the lounge is meant to be a community space for an often-isolated patient population.

May 10, 2024

The Seaport-based biotechnology company plans to reduce its labor expenses at least 25%. The company also wants to terminate and sublease extra space.

May 10, 2024

Just days before its initial deadline, U.S. regulators say they need more time to decide whether or not to approve Moderna's respiratory syncytial virus (RSV) vaccine.